Publications by authors named "M H Sugarman"

Plasma-to-autopsy studies are essential for validation of blood biomarkers and understanding their relation to Alzheimer's disease (AD) pathology. Few such studies have been done on phosphorylated tau (p-tau) and those that exist have made limited or no comparison of the different p-tau variants. This study is the first to use immunoprecipitation mass spectrometry (IP-MS) to compare the accuracy of eight different plasma tau species in predicting autopsy-confirmed AD.

View Article and Find Full Text PDF

We explored the roles of community health workers (CHWs) working in Medicaid Managed Care Organizations in Louisiana by conducting 10 interviews with CHWs, supervisors, and administrators. We identified 6 themes: CHWs' backgrounds and training; roles as they related to nationally recognized competencies; team integration; who CHWs serve and how members are identified; metrics for success; and the effects of COVID. CHWs are hired for their community connections.

View Article and Find Full Text PDF
Article Synopsis
  • This study investigated the effectiveness of plasma glial fibrillary acidic protein (GFAP) as a biomarker for cognitive impairment in Alzheimer's disease (AD) compared to other biomarkers like neurofilament light chain (NfL) and phosphorylated tau (p-tau).
  • The research analyzed plasma samples from 567 participants and correlated GFAP levels with cognitive functions and dementia severity, finding that GFAP was significantly more effective in differentiating between normal cognition and AD dementia or mild cognitive impairment.
  • While higher GFAP levels were linked to worse cognitive performance and dementia symptoms, it specifically predicted memory decline over time but did not indicate progression to mild cognitive impairment or dementia.
View Article and Find Full Text PDF

Blood-based biomarkers such as tau phosphorylated at threonine 181 (phosphorylated-tau181) represent an accessible, cost-effective and scalable approach for the in vivo detection of Alzheimer's disease pathophysiology. Plasma-pathological correlation studies are needed to validate plasma phosphorylated-tau181 as an accurate and reliable biomarker of Alzheimer's disease neuropathological changes. This plasma-to-autopsy correlation study included participants from the Boston University Alzheimer's Disease Research Center who had a plasma sample analysed for phosphorylated-tau181 between 2008 and 2018 and donated their brain for neuropathological examination.

View Article and Find Full Text PDF

The present study investigated abbreviation methods for the Test of Memory Malingering (TOMM) in relation to traditional manual-based test cutoffs and independently derived more stringent cutoffs suggested by recent research (≤48 on Trial 2 or 3). Consecutively referred outpatient U.S.

View Article and Find Full Text PDF